Mireia Margeli

Summary

Country: Spain

Publications

  1. pmc The prognostic value of BRCA1 mRNA expression levels following neoadjuvant chemotherapy in breast cancer
    Mireia Margeli
    Medical Oncology Service, Department of Medicine, Catalan Institute of Oncology, Hospital Germans Trias i Pujol and Autonomous University of Barcelona, Badalona, Spain
    PLoS ONE 5:e9499. 2010
  2. ncbi Phase II non-randomized study of three different sequences of docetaxel and vinorelbine in patients with advanced non-small cell lung cancer
    Jose Miguel Sanchez
    Medical Oncology Service, Hospital Germans Trias i Pujol, Ctra Canyet s n, 08916 Badalona, Barcelona, Spain
    Lung Cancer 38:309-15. 2002
  3. pmc Prognostic value of hematogenous dissemination and biological profile of the tumor in early breast cancer patients: a prospective observational study
    Montserrat Solà
    Nuclear Medicine Department, University Hospital Germans Trias i Pujol, Carretera del Canyet, Badalona, Spain
    BMC Cancer 11:252. 2011
  4. ncbi Methylation patterns and K-ras mutations in tumor and paired serum of resected non-small-cell lung cancer patients
    Jose Luis Ramirez
    Medical Oncology Service, Hospital Germans Trias i Pujol, Ctra Canyet, s n 08916, Barcelona, Spain
    Cancer Lett 193:207-16. 2003
  5. doi Biweekly vinorelbine and tegafur/uracil in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: GEICAM 2000-02 phase II study
    Antonio Anton
    Medical Oncology Service, Hospital Universitario Miguel Servet, Zaragoza, Spain
    Clin Transl Oncol 13:281-6. 2011
  6. doi Phase I/II docetaxel plus concurrent hyperfractionated radiotherapy in locally advanced unresectable head and neck cancer (TAX.ES1.102 study)
    Agusti Barnadas
    Department of Medical Oncology, Institut Catala d Oncologia, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain
    Clin Transl Oncol 13:254-60. 2011
  7. ncbi Weekly regimen of irinotecan/docetaxel in previously treated non-small cell lung cancer patients and correlation with uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) polymorphism
    Albert Font
    Medical Oncology Service, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain
    Invest New Drugs 21:435-43. 2003

Collaborators

  • Rafael Rosell
  • Gustavo Tapia
  • Ricard Mesia
  • Albert Abad
  • Montserrat Solà
  • Susana Benlloch
  • Agusti Barnadas
  • Jose Miguel Sanchez
  • Antonio Anton
  • Albert Font
  • Jose Luis Manzano
  • Jose Javier Sanchez
  • Miquel Taron
  • Jose Luis Ramirez
  • Martin Richardet
  • Jesús Florián
  • José M de Vega
  • Maria Lomas
  • Ana González-Quintás
  • Margarita Majem
  • Vicente Valentí
  • Nuria Ribelles
  • Antonio Lopez-Pousa
  • Ariadna Lloansí
  • Juan Lao
  • Lluís Anglada
  • Ramon Galiana
  • Ana Belén Paules
  • Manuel Ramos
  • Antonio Arellano
  • Javier Gayo
  • Eva Martinez-Balibrea
  • Julio Astudillo
  • Carme Sarries
  • Pedro Lopez de Castro
  • Barbara Roig
  • Cristina Queralt
  • Daniel Escuin
  • Itziar de Aguirre
  • Mónica Guillot
  • Carme Balañà

Detail Information

Publications7

  1. pmc The prognostic value of BRCA1 mRNA expression levels following neoadjuvant chemotherapy in breast cancer
    Mireia Margeli
    Medical Oncology Service, Department of Medicine, Catalan Institute of Oncology, Hospital Germans Trias i Pujol and Autonomous University of Barcelona, Badalona, Spain
    PLoS ONE 5:e9499. 2010
    ..Furthermore, sporadic ovarian cancer patients with low levels of BRCA1 mRNA have longer survival following platinum-based chemotherapy than patients with high levels of BRCA1 mRNA...
  2. ncbi Phase II non-randomized study of three different sequences of docetaxel and vinorelbine in patients with advanced non-small cell lung cancer
    Jose Miguel Sanchez
    Medical Oncology Service, Hospital Germans Trias i Pujol, Ctra Canyet s n, 08916 Badalona, Barcelona, Spain
    Lung Cancer 38:309-15. 2002
    ..Non-hematologic toxicities were mild in all three schedules. For future studies, schedule A with lower doses is recommended...
  3. pmc Prognostic value of hematogenous dissemination and biological profile of the tumor in early breast cancer patients: a prospective observational study
    Montserrat Solà
    Nuclear Medicine Department, University Hospital Germans Trias i Pujol, Carretera del Canyet, Badalona, Spain
    BMC Cancer 11:252. 2011
    ....
  4. ncbi Methylation patterns and K-ras mutations in tumor and paired serum of resected non-small-cell lung cancer patients
    Jose Luis Ramirez
    Medical Oncology Service, Hospital Germans Trias i Pujol, Ctra Canyet, s n 08916, Barcelona, Spain
    Cancer Lett 193:207-16. 2003
    ..K-ras mutations in serum correlated significantly with survival (P=0.01)...
  5. doi Biweekly vinorelbine and tegafur/uracil in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: GEICAM 2000-02 phase II study
    Antonio Anton
    Medical Oncology Service, Hospital Universitario Miguel Servet, Zaragoza, Spain
    Clin Transl Oncol 13:281-6. 2011
    ..To assess the efficacy and safety profile of biweekly vinorelbine and tegafur/uracil (UFT) as treatment in patients with metastatic breast cancer previously treated with anthracyclines and taxanes...
  6. doi Phase I/II docetaxel plus concurrent hyperfractionated radiotherapy in locally advanced unresectable head and neck cancer (TAX.ES1.102 study)
    Agusti Barnadas
    Department of Medical Oncology, Institut Catala d Oncologia, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain
    Clin Transl Oncol 13:254-60. 2011
    ..Concurrent chemotherapy and radiotherapy is recommended for the treatment of locally advanced unresectable head and neck (H&N) cancer...
  7. ncbi Weekly regimen of irinotecan/docetaxel in previously treated non-small cell lung cancer patients and correlation with uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) polymorphism
    Albert Font
    Medical Oncology Service, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain
    Invest New Drugs 21:435-43. 2003
    ....